Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies

Regulations by 2FIRSTS.ai
Jun.24.2024
Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies
Australia government withdraws e-cigarette sales plan, allowing non-prescription purchase at pharmacies. Health Minister Mark Butler reached agreement with Greens.

According to The Sydney Morning Herald on June 24th, the Australian government has withdrawn its plan to allow e-cigarettes to be sold commercially. E-cigarettes will not require a prescription to be purchased in pharmacies.

 

Minister of Health Mark Butler reached an agreement with the Green Party on Monday, June 24th, to relax the ban on e-cigarettes scheduled to take effect in July. This was in order to pass legislation in the Senate to prohibit retail sales, as the initially stricter proposal did not have the support of the majority of senators.

 

According to sources familiar with the agreement, after the ban on e-cigarettes takes effect in July, consumers will still need a doctor's prescription to purchase e-cigarettes. However, in the future, adults will not need a prescription from a general practitioner to buy e-cigarettes from pharmacies. They will only need to speak with a pharmacist and can purchase them over the counter.

 

At the same time, individuals under the age of 18 are allowed to purchase e-cigarettes with a prescription from a clinician if deemed appropriate.

 

The government has promised to provide additional funding to support young people in quitting e-cigarettes.

 

E-cigarettes sold in pharmacies will still be regulated and must comply with standard packaging requirements.

 

Butler's adjustment is a concession to the substantial political capital invested in the success of the e-cigarette ban. He will announce the full details of the changes later today.

 

Butler previously proposed the idea of allowing people to purchase e-cigarettes from pharmacies without a prescription, but he stated that this would only be considered if the prescription drug model is not successful.

 

He stated in November of last year,

 

Health ministers are interested in exploring whether e-cigarettes can be provided solely by pharmacists in pharmacies, where similar products are often located behind the counter and require interaction with a pharmacist but not a doctor's prescription.

 

We have not made a decision yet, but I have said that if the proposed reform does not adequately ensure that people with genuine treatment needs can access e-cigarettes, we will consider other options.

 

Both the Greens and the National Party have expressed doubt about the proposal put forward by the Labor Party to ban all retail sales of e-cigarettes and require a prescription from a general practitioner to obtain them from a pharmacy. This is a stricter version of the law first proposed by former Coalition Health Minister Greg Hunt in 2021.

 

The Green Party and the two major political parties are aligned in their desire to prevent children from purchasing e-cigarettes from unlicensed stores.

 

However, the Greens' health spokesperson, Jordon Steele-John, expressed concerns about the difficulties and costs of quitting smoking for those who need to make an appointment with a general practitioner in order to get a prescription. The Department of Health's analysis of Butler's original plan indicates that 450,000 Australians per year will seek e-cigarette prescriptions, requiring nearly one million visits to general practitioners.

 

John also expressed skepticism towards the prohibition model, pointing out that drug bans have proven to be ineffective.

 

Many young Australians are using e-cigarettes, banning the sale of e-cigarettes could potentially become a political issue.

 

No one should be punished for personal use of e-cigarettes. Prohibition policies for drugs have failed. Many people under the age of 18 are becoming addicted to nicotine. We need to ensure there are proper resources in place to help these individuals quit using e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13